BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Poised as Key Innovative Leader at Forefront in Neurology Tech

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, is a recognized leading innovative player in the brain monitoring space. The company continues to be at the forefront of what is next in neurology technology. In a Tech Times feature, Brain Scientific’s Marketing Director Irina Nazarova outlined key brain monitoring trends to watch in 2021, including the fact that brain monitoring is becoming as popular and widespread as monitoring pulse or heart rate. Several potential applications have swelled, and EEG monitoring is no longer a preserve of clinicians and expert neuroscientific researchers. A recent article reads, “Exciting new opportunities are potentially in front of EEG technology. EEG-based products go beyond the medical space and are on their way to penetrate new sectors and find more uses. Brain Scientific is committed to remaining a key innovative leader in what could potentially be a rapidly growing market over the next years.”

To view the full article, visit https://ibn.fm/LojNW

About Brain Scientific Inc.

Brain Scientific is a commercial-stage healthcare company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about the company’s corporate strategy, devices, or for investor relations, visit www.BrainScientific.com.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Highlights Two Years of Clinical Milestones Across Oncology and Rare Disease Programs 

Oncotelic Therapeutics (OTCQB: OTLC), a clinical-stage biopharmaceutical company developing transformative oncology and immunotherapy treatments, announced…

1 day ago

BioMedNewsBreaks – HealthLynked Corp. (OTCQB: HLYK) Expands IP Portfolio with New U.S. Patent Filings

HealthLynked (OTCQB: HLYK), a leader in patient-centric healthcare technology, announced the submission of two new…

2 days ago

BioMedNewsBreaks – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Featured in MarketScreener Editorial on Targeted AI Applications

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device company advancing imaging-based products for…

3 days ago

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Reports 51% Revenue Growth, Strong Cash Position to Advance AVERSA Fentanyl

Nutriband (NASDAQ: NTRB) reported financial results for the six months ended July 31, 2025, highlighted…

3 days ago

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Engages IBN to Lead Corporate Communications

Oncotelic Therapeutics (OTCQB: OTLC), a clinical-stage biopharmaceutical company developing RNA-based, immunotherapy and targeted treatments for…

3 days ago

BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) CEO Panna Sharma Featured on IBN’s BioMedWire Podcast 

Lantern Pharma (NASDAQ: LTRN), an AI-driven oncology company developing targeted cancer therapies with its proprietary…

4 days ago